BCRX

7.59

0.26% 0.02

Dopo l'orario di chiusura: 7.57 -0.02 -0.26%

Biocryst Pharmaceuticals Inc (BCRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BCRX Giù? Forum Previsione

Precedente Chiudi:

$7.57

Aprire:

$7.635

Volume 24 ore:

4.92M

Relative Volume:

1.00

Capitalizzazione di mercato:

$1.60B

Reddito:

$557.51M

Utile/perdita netta:

$-35.71M

Rapporto P/E:

-42.17

EPS:

-0.18

Flusso di cassa netto:

$15.50M

1 W Prestazione:

-1.43%

1M Prestazione:

+7.20%

6M Prestazione:

-26.81%

1 anno Prestazione:

+0.80%

Intervallo 1D:

$7.435

$7.915

Intervallo di 1 settimana:

$7.23

$7.915

Portata 52W:

$6.00

$11.31

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Nome

Biocryst Pharmaceuticals Inc

Settore

Healthcare (1131)

Industria

Drug Manufacturers - Specialty & Generic (85)

Telefono

919-859-1302

Indirizzo

4505 EMPEROR BOULEVARD, DURHAM, NC

Dipendente

580

Cinguettio

@biocrystpharma

Prossima data di guadagno

2025-02-24

Ultimi documenti SEC

BCRX's Discussions on Twitter

Confronta BCRX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BCRX Biocryst Pharmaceuticals Inc	7.59	1.59B	557.51M	-35.71M	15.50M	-0.18
ZTS Zoetis Inc	120.98	52.29B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	14.61	45.27B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	9.83	42.39B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	30.13	34.18B	16.88B	666.71M	251.19M	0.6132
UTHR United Therapeutics Corp	500.30	21.27B	3.08B	1.24B	1.07B	25.61

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-10-15	Ripresa	TD Cowen	Buy
2025-10-01	Downgrade	Evercore ISI	Outperform → In-line
2025-04-29	Iniziato	Cantor Fitzgerald	Overweight
2025-02-25	Iniziato	Wedbush	Outperform
2023-11-20	Ripresa	JP Morgan	Overweight
2023-09-18	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-08-04	Aggiornamento	Jefferies	Hold → Buy
2023-07-13	Aggiornamento	BofA Securities	Neutral → Buy
2023-02-22	Aggiornamento	Needham	Hold → Buy
2022-11-02	Aggiornamento	Evercore ISI	In-line → Outperform
2022-08-05	Downgrade	Evercore ISI	Outperform → In-line
2022-08-05	Downgrade	Oppenheimer	Outperform → Perform
2022-04-18	Downgrade	Barclays	Overweight → Equal Weight
2022-04-11	Downgrade	BofA Securities	Buy → Neutral
2021-12-10	Iniziato	Oppenheimer	Outperform
2021-08-06	Downgrade	Jefferies	Buy → Hold
2021-08-03	Iniziato	Cantor Fitzgerald	Overweight
2021-03-01	Iniziato	Cowen	Outperform
2020-09-29	Ripresa	JP Morgan	Overweight
2020-06-17	Iniziato	BTIG Research	Neutral
2020-05-05	Aggiornamento	Barclays	Equal Weight → Overweight
2019-11-15	Aggiornamento	BofA/Merrill	Neutral → Buy
2019-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2018-11-16	Ripresa	Piper Jaffray	Overweight
2018-08-08	Ripresa	JP Morgan	Overweight
2018-07-17	Aggiornamento	BofA/Merrill	Underperform → Neutral
2018-06-22	Iniziato	Seaport Global Securities	Neutral
2018-01-02	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2017-12-20	Iniziato	Barclays	Equal Weight
2017-09-15	Iniziato	RBC Capital Mkts	Sector Perform
2017-09-06	Aggiornamento	JP Morgan	Neutral → Overweight
2017-09-06	Aggiornamento	Jefferies	Hold → Buy
2017-02-16	Iniziato	Ladenburg Thalmann	Buy
2016-08-12	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-08-04	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Reiterato	FBR Capital	Outperform
2016-02-09	Downgrade	JP Morgan	Overweight → Neutral
2016-02-09	Downgrade	Needham	Buy → Hold

Mostra tutto

Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie

Dec 15, 2025

Why are retail traders going gaga over BioCryst Pharma stock today? - MSN

Dec 15, 2025

Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025? - Yahoo Finance

Dec 15, 2025

FDA extends Orladeyo approval to children as young as 2 - Angioedema News

Dec 15, 2025

BCRX: HC Wainwright Maintains Buy Rating, Raises Price Target to $32 | BCRX Stock News - GuruFocus

Dec 15, 2025

HC Wainwright Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat

Dec 15, 2025

BioCryst Pharma stock rating reiterated by Citizens on pediatric approval - Investing.com

Dec 15, 2025

Dec 14, 2025

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Dec 14, 2025

Dec 13, 2025

The Technical Signals Behind (BCRX) That Institutions Follow - news.stocktradersdaily.com

Dec 13, 2025

Aug Highlights: Is BioCryst Pharmaceuticals Inc stock oversold or undervaluedJuly 2025 Sentiment & Risk Controlled Swing Alerts - moha.gov.vn

Dec 13, 2025

FDA approves BioCryst’s oral pellet version of rare disease drug for children - WKZO

Dec 13, 2025

Alkeon Capital Management LLC Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

Dec 13, 2025

Dec 12, 2025

BioCryst wins FDA approval for Orladeyo oral pellets - MSN

Dec 12, 2025

FDA approves BioCryst's oral pellet version of swelling disorder drug for children - Reuters

Dec 12, 2025

BioCryst Pharma stock maintains Buy rating at TD Cowen on Orladeyo pediatric approval - Investing.com

Dec 12, 2025

BioCryst’s Orladeyo wins expanded FDA approval - The Pharma Letter

Dec 12, 2025

BioCryst Gets FDA Approval To Treat Rare Childhood Swelling Disorder With Oral Drug - Benzinga

Dec 12, 2025

BioCryst Announces Board Chair Transition Plan - TipRanks

Dec 12, 2025

FDA approves berotralstat for patients aged 2 to 11 years with hereditary angioedema - Contemporary Pediatrics

Dec 12, 2025

Sector Update: Health Care Stocks Edge Higher Premarket Friday - marketscreener.com

Dec 12, 2025

Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? - Stocktwits

Dec 12, 2025

BioCryst stock rises after FDA approves ORLADEYO oral pellets for children - Investing.com Canada

Dec 12, 2025

FDA Approves BioCryst's (BCRX) Oral Pellet Formulation of Orlade - GuruFocus

Dec 12, 2025

FDA approves BioCryst’s ORLADEYO oral pellets for HAE in children - Investing.com

Dec 12, 2025

BioCryst wins FDA nod for Orladeyo oral pellets (BCRX:NASDAQ) - Seeking Alpha

Dec 12, 2025

FDA Gives Green Light to BioCryst's (BCRX) ORLADEYO for Pediatri - GuruFocus

Dec 12, 2025

FDA approves BioCryst’s ORLADEYO oral pellets for HAE in children By Investing.com - Investing.com Australia

Dec 12, 2025

BioCryst Pharmaceuticals Announces FDA Approval of ORLADEYO Oral Pellets as First Targeted Prophylactic Therapy for Pediatric Patients with HAE Aged 2 and Older - Quiver Quantitative

Dec 12, 2025

FDA expands approval of BioCryst's rare disease drug for use in young children - marketscreener.com

Dec 12, 2025

BioCryst (Nasdaq: BCRX) gains FDA nod for 1st oral HAE prophylaxis, ages 2- - Stock Titan

Dec 12, 2025

Nebula Research & Development LLC Invests $2.57 Million in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

Dec 12, 2025

Dec 11, 2025

BioCryst Pharmaceuticals announces board chair transition following retirement notice By Investing.com - Investing.com Nigeria

Dec 11, 2025

BioCryst Pharmaceuticals announces board chair transition following retirement notice - Investing.com India

Dec 11, 2025

Dec 10, 2025

Hereditary Angioedema Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in the Therapeutics | DelveInsight - The Globe and Mail

Dec 10, 2025

Dec 09, 2025

Hood River Capital Management LLC Buys New Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

Dec 09, 2025

Dec 08, 2025

Trading Action: Can BioCryst Pharmaceuticals Inc stock hit analyst price targetsJuly 2025 Catalysts & Trade Opportunity Analysis Reports - moha.gov.vn

Dec 08, 2025